Literature DB >> 29688144

Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study.

G Y Ahn1, D Kim1, S Won2, S T Song1, H-J Jeong1, I-W Sohn1, S Lee1, Y B Joo3, S-C Bae1.   

Abstract

Objective The objective of this paper is to identify the prevalence, risk factors, and impact on mortality of neuropsychiatric systemic lupus erythematosus (NPSLE). Methods Patients from the Hanyang BAE lupus cohort were registered and followed from 1998 to 2015. NPSLE was defined using American College of Rheumatology (ACR) case definitions and Ainiala criteria. Demographics, autoantibodies, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and Systemic Lupus International Collaborating Clinic (SLICC)/ACR Damage Index were collected at baseline and then annually. Mortality data were derived by linking data from the Korean National Statistics Office. Multivariable logistic regression and Cox regression analysis were conducted in the inception cohort to assess the risk factors and mortality impact of NPSLE. Results Of 1121 registered patients, 429 (38.3%) had NPSLE manifestations according to ACR criteria and 216 (19.3%) by Ainiala criteria. In multivariable logistic regression analysis, higher SLEDAI (OR 1.08, CI 1.01-1.16, p = 0.02) and antiphospholipid antibody positivity (OR 1.72, CI 1.03-2.87, p = 0.04) at SLE diagnosis increased NPSLE risk, while elevated anti-dsDNA antibodies (OR 0.43, CI 0.24-0.78, p < 0.01) and greater education duration (OR 0.92, CI 0.85-1.00, p = 0.04) showed reduced risk of NPSLE. Cox proportional hazard models demonstrated that presence of NPSLE had a three-fold increased risk of mortality (HR 3.09, CI 1.03-9.21, p = 0.04), especially in patients with focal CNS NPSLE (HR = 7.83, CI 2.12-28.96, p < 0.01). Conclusion Higher SLEDAI, antiphospholipid antibody positivity, absence of anti-dsDNA antibody at SLE diagnosis, and fewer years of education are risk factors for development of NPSLE. Presence of NPSLE, especially focal CNS NPSLE, increased the risk of mortality in SLE patients.

Entities:  

Keywords:  Lupus erythematosus; mortality; neurological; prevalence; psychiatric; risk factors; systemic

Mesh:

Substances:

Year:  2018        PMID: 29688144     DOI: 10.1177/0961203318772021

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  15 in total

Review 1.  Atypical Pediatric Demyelinating Diseases of the Central Nervous System.

Authors:  Regina M Troxell; Alison Christy
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

Review 2.  Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials.

Authors:  Nina Kello; Erik Anderson; Betty Diamond
Journal:  Arthritis Rheumatol       Date:  2019-08-07       Impact factor: 10.995

3.  Disrupted resting-state interhemispheric functional connectivity in systemic lupus erythematosus patients with and without neuropsychiatric lupus.

Authors:  Yi-Ling Wang; Mu-Liang Jiang; Li-Xuan Huang; Xia Meng; Shu Li; Xiao-Qi Pang; Zi-San Zeng
Journal:  Neuroradiology       Date:  2021-08-11       Impact factor: 2.804

4.  Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the 'Attikon' cohort.

Authors:  D Nikolopoulos; M Kostopoulou; A Pieta; T Karageorgas; D Tseronis; K Chavatza; S Flouda; P Rapsomaniki; A Banos; E Kremasmenou; V Tzavara; P Katsimbri; A Fanouriakis; D T Boumpas
Journal:  Lupus       Date:  2020-02-27       Impact factor: 2.911

5.  Neuropsychiatric Lupus Erythematosus: Future Directions and Challenges; a Systematic Review and Survey.

Authors:  Yongwen Zhang; Huanhuan Han; Lanfang Chu
Journal:  Clinics (Sao Paulo)       Date:  2020-04-17       Impact factor: 2.365

6.  Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China.

Authors:  Shangzhu Zhang; Meng Li; Li Zhang; Ziqian Wang; Qiang Wang; Hui You; Yanhong Wang; Mengtao Li; Xiaofeng Zeng
Journal:  J Immunol Res       Date:  2021-01-18       Impact factor: 4.818

7.  Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands.

Authors:  Rory C Monahan; Rolf Fronczek; Jeroen Eikenboom; Huub A M Middelkoop; Liesbeth J J Beaart-van de Voorde; Gisela M Terwindt; Nic J A van der Wee; Frits R Rosendaal; Tom W J Huizinga; Margreet Kloppenburg; Gerda M Steup-Beekman
Journal:  Lupus       Date:  2020-10-20       Impact factor: 2.911

8.  Fatal cerebral venous sinus thrombosis as a manifestation of uncontrolled systemic lupus erythematosus in a young African female.

Authors:  Abid M Sadiq; Emmanuel V Assey; Adnan M Sadiq; Marieke C J Dekker; William P Howlett
Journal:  Clin Case Rep       Date:  2021-07-06

9.  Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort.

Authors:  John G Hanly; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul R Fortin; Dafna D Gladman; Murray B Urowitz; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Rosalind Ramsey-Goldman; Susan Manzi; Andreas Jonsen; Graciela S Alarcón; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2021-10-29       Impact factor: 15.483

10.  A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants.

Authors:  Jackrapong Bruminhent; Suphanan Autto; Porpon Rotjanapan; Pintip Ngarmjanyaporn; Asalaysa Bushyakanist; Suppachok Kirdlarp; Pichaya O-Charoen; Chavachol Setthaudom; Prapaporn Pisitkun
Journal:  Open Forum Infect Dis       Date:  2021-05-16       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.